Medigene AG and the National Cancer Institute (NCI) will collaborate to evaluate the potential of Medigene's proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors. NCI is part of the National Institutes of Health. Medigene's TCR-T Therapy Platform: Medigene's immunotherapies help activate the patient's own defense mechanisms by harnessing T cells in the battle against cancer.

Medigene's end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, Precision Pairing) and development optimization technologies (Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2SeventyBio, and Hongsheng Sciences, continue to validate the platform's assets & technologies.